A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum

Author： Royce Melanie E.   Rowinsky Eric K.   Hoff Paulo M.   Coyle John   DeJager Robert   Pazdur Richard   Saltz Leonard B.  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.22, Iss.1, 2004-01, pp. : 53-61

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer

By Ajani Jaffer   Takimoto Chris   Becerra Carlos   Silva Alejandro   Baez Luis   Cohn Allen   Major Pierre   Kamida Makio   Feit Kevie   Jager Robert  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 479-484

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies

By Chen Eric   Batist Gerald   Siu Lillian   Bangash Naeema   Maclean Martha   McIntosh Lynn   Miller Wilson   Oza Amit   Lathia Chetan   Petrenciuc Oana   Seymour Lesley  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 455-465

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer

By Denduluri Neelima   Lee James   Walshe Janice   Berman Arlene   Vatas Ujala   Chow Catherine   Steinberg Seth   Cox Michael   Low Jennifer   Swain Sandra  

Investigational New Drugs, Vol. 25, Iss. 1, 2007-02 ,pp. : 63-67

Springer Publishing Company

Access to resources Recommend Favorite

A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers

By Gelmon K.   Hirte H.   Fisher B.   Walsh W.   Ptaszynski M.   Hamilton M.   Onetto N.   Eisenhauer E.  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 263-275

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks

By Johnson Peter   Geldart Thomas   Fumoleau Pierre   Pinel Marie-Claire   Nguyen Laurent   Judson Ian  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 223-231

Springer Publishing Company

Access to resources Recommend Favorite